Login to Your Account

Santaris: Still 'Confident,' Moving Forward

GSK Picks a Side in MiR-122 IP Battle; Inks Regulus HCV Deal

By Jennifer Boggs

Friday, February 26, 2010
Regulus Therapeutics Inc. nailed down a deal with GlaxoSmithKline plc to develop an miR-122 antagonist in hepatitis C virus in a $150 million-plus partnership that cast a spotlight on intellectual property rights relating to the liver-specific microRNA target, given that GSK previously declined an option for a clinical-stage drug from Danish firm Santaris Pharma A/S. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription